Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symmetrix names new chief scientific officer
Dr Shebuski, a cardiovascular pharmacologist, has broad experience in cardiovascular drug development with over 25 years in the pharmaceutical industry. He will be responsible for the pre-clinical and
Dr Shebuski, a cardiovascular pharmacologist, has broad experience in cardiovascular drug development with over 25 years in the pharmaceutical industry. He will be responsible for the pre-clinical and
AVI-6002 and AVI-6003 are novel analogs based on Avi’s phosphorodiamidate morpholino oligomers antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the
Under the terms of the agreement, Archemix will receive $27.5 million in upfront payments from GlaxoSmithKline (GSK), including a $6.5 million equity investment by GSK in the company.
The first was for Roche’s thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The
The company is funding the transaction entirely from Sunstone’s existing cash flow and, in the future, intends to acquire a majority stake and potentially consolidate Shengda’s financial results.
Under terms of this new agreement, Breckenridge will submit an abbreviated new drug application (ANDA) to the FDA in 2009 for the product which is in development by
Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. The lawsuits are in response to the submission
The study evaluated the dose response, efficacy and safety of five doses of GW642444 (‘444) administered once-daily for four weeks. All doses achieved statistically significant increases in lung
Wafik El-Deiry, professor of medicine, genetics and pharmacology at the University of Pennsylvania School of Medicine and associate director for physician-scientist training in hematology/oncology at the University of
The first patient was enrolled at the University of Alabama at Birmingham. The study will be conducted at approximately 15 to 20 centers in the US, and will